RE: Sierra 2021 Year End10 Mar 2022 13:31
Krone - thanks for posting the link.
From the report -
"While we have currently deprioritized development of SRA737, we are exploring options for future development of this product candidate, if any. However, there can be no assurance that we will successfully obtain development support or the funding, through partnership or collaborations, necessary to advance SRA737 on commercially reasonable terms, or at all."
and
"In September 2016, we entered into an exclusive license agreement with CRT Pioneer Fund LP (CPF) for worldwide rights, know-how and materials to develop SRA737, a small molecule inhibitor targeting Chk1, a promising therapeutic target to treat cancer. If we fail to meet our diligence and other obligations under the license agreement, we could lose our rights to this technology."
and
"In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before momelotinib, SRA515, or SRA737 can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent."
I presume that last quote is just Sierra covering their backs in a 'don't say we didn't warn you' kind of way.
Anyway, my take is we shouldn't hold our breath for SRA737 money any time soon.
Although the report considers SRA737 to have great potential, it seems Sierra doesn't have the funding to do much with it for now.
Regards.